BF 114
Alternative Names: BF-114; siRNA targeting Beta2-spectrin - BullFrog AILatest Information Update: 28 Feb 2026
At a glance
- Originator The George Washington University
- Developer BullFrog AI
- Class Antineoplastics; Hepatoprotectants; Obesity therapies; Small interfering RNA
- Mechanism of Action RNA interference; SPTBN1 protein expression inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Obesity
- No development reported Liver cancer; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
Most Recent Events
- 28 Feb 2026 No recent reports of development identified for research development in Liver-cancer in USA (Parenteral)
- 28 Feb 2026 No recent reports of development identified for research development in Non-alcoholic-fatty-liver-disease in USA (Parenteral)
- 28 Feb 2026 No recent reports of development identified for research development in Non-alcoholic-steatohepatitis in USA (Parenteral)